ClinicalTrials.gg
CompletedNCT06492031oSCARUpdated Apr 15, 2026

Observational Study of the Use of Extraneal in Peritoneal Dialysis in Patients

An observational study in Chronic Renal Failure, sponsored by Vantive Health LLC. Completed at 10 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Vantive Health LLC (formerly part of Baxter Healthcare Corporation) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
439
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation — none open to participants now, none under way, none of them phase 3. Kidney Failure, Chronic · Baxter Healthcare Corporation.

Started
2024
the only one that year
Observational
4 of 33
none open now
Registered
33rd of 33
by date

Among the 33 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation, this one is the only one that started in 2024, is one of 4 observational ones, and was the 33rd registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

None of the 33 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation is open now. The open studies under Kidney Failure, Chronic, anywhere →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness and safety of icodextrin and glucose peritoneal dialysis (PD) solutions for the long dwell exchange in PD patients with continuous ambulatory peritoneal dialysis (CAPD), and to describe medical resource utilization in patients with PD on icodextrin.

Read the detailed description

Patients will be divided into icodextrin dialysate group (ICO group) and glucose dialysate group (glucose group).

ICO group: Patient data will be collected retrospectively and prospectively. Patients currently prescribed icodextrin will be recruited and enrolled. Data for these patients will included both retrospective historical data collection as well as a prospective collection of additional data. Within the relative look-back period (i.e., within 6 months before the launch of the study site), data will be collected from baseline (i.e., the most recent medical records prior to the first prescription of icodextrin) up to signing of the ICF. After providing informed consent, patient data will be prospectively collected for 12 months.

Additionally, any patients who are first prescribed icodextrin therapy after the launch of the study site will also be recruited and enrolled prospectively and data will be collected up to 12 months from enrollment for this group. For these patients, baseline will be defined as the most recent medical record from the time of signing the ICF to the first prescription of icodextrin.

Glucose group: Patient data will be collected retrospectively from CAPD patients followed up in the peritoneal dialysis center from July 1, 2018, to December 31, 2018. Retrospective data will be collected up to 12 months from baseline (i.e., the most recent peritoneal equilibration test date before December 31, 2018, in the peritoneal dialysis center).

The effectiveness and safety between the 2 groups will be analyzed.

03

Conditions studied

  • Chronic Renal Failure

Keywords

  • Continuous ambulatory peritoneal dialysis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients in China prescribed icodextrin or glucose PD solutions for continuous ambulatory peritoneal dialysis.

Eligibility criteria

Inclusion Criteria for patients enrolled retrospectively in the ICO Group:

  • Age ≥ 18 years old at first prescription of icodextrin, male or female;
  • With a definite diagnosis of CRF and on maintenance PD ≥ 3 months;
  • On CAPD treatment;
  • Being treated with icodextrin long dwell exchange with an icodextrin prescription ≤ 6 months with essential baseline information(including age, gender, PD vintage, presence of diabetes or not, PET, and assessment of dialysis adequacy);
  • Voluntarily sign the form (ICF) and be willing to complete the study visits as required by the investigator (For death cases, exemption of the informed consent will be applied with approval of the ethics committee).

Inclusion Criteria for patients enrolled prospectively in the ICO Group:

  • Age ≥ 18 years old, male or female;
  • Patients with a definite diagnosis of CRF and on maintenance PD ≥ 3 months;
  • On CAPD treatment, with planned prescription for icodextrin;
  • Voluntarily sign the ICF and be willing to complete the study visits as required by the investigator.

Exclusion Criteria for the ICO Group:

  • Those with combined HD within 30 days prior to enrolment;
  • History of peritonitis within 30 days prior to enrolment or presence of acute or chronic exit site infection or tunnel infection at enrolment;
  • Participation in another interventional study within 30 days prior to enrolment or concurrently with this study;
  • Allergy to any components of Icodextrin;
  • Pregnancy or in lactation;
  • Any other condition for which the investigator considers the patient to be unsuitable for participation in this study.

Inclusion Criteria for the Glucose Group:

  • Age ≥ 18 years at baseline, male or female;
  • Those with a definitive diagnosis of CRF prior to baseline and eligible for CAPD treatment with Baxter's glucose PD solutions between July 1, 2018 and December 31, 2018;
  • On maintenance PD ≥ 3 months;
  • Essential baseline information (including age, gender, PD vintage, presence of diabetes or not, peritoneal transport status, dialysis adequacy assessment, 24-hour urine volume);
  • Any prescription of Baxter's glucose PD solutions and medical records of clinical events within 1 year from baseline.

Exclusion Criteria for the Glucose Group:

  • Those with combined HD within 30 days prior to baseline;
  • History of peritonitis within 30 days prior to baseline or presence of acute or chronic exit site infection or tunnel infection during baseline;
  • Prescription of non-Baxter PD solutions within 1 month prior to baseline.
  • Patients enrolled in the ICO group.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
439 participants (actual)
Patient registry
No

Groups and cohorts

  • Icodextrin (ICO) Group

    Icodextrin is only intended for intraperitoneal administration and is recommended for long dwell during CAPD (i.e., recommended dwell time from 8-16 hours). Administration will be done at a rate that is comfortable for the patient, typically within 10-20 minutes.

    Drug: Icodextrin Peritoneal Dialysis Solution

  • Glucose Group

    During CAPD, 2L of dialysis fluid is instilled into the peritoneal cavity and allowed to dwell for a certain period. The dwell time typically ranges from 4 to 8 hours during the day and 8 to 12 hours at night. This process is repeated 3 to 4 times a day, for 6 to 7 days a week. The frequency of solution exchanges may vary for each individual to achieve desired biochemical and solution control. Most solution exchanges utilize a 1.5% or 2.5% glucose dialysis solution. If more solution removal is required, a 4.25% glucose peritoneal dialysis solution can be used. Regular measurement of the patient's weight can be used to guide the setting of ultrafiltration volume.

    Drug: Glucose Peritoneal Dialysis Solution

Interventions

  • DrugIcodextrinStudies of IcodextrinIcodextrin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The treatment modality, treatment frequency, treatment dose, duration of dwell, and length of treatment, as determined and supervised by a prescribing physician experienced in treating ESRD with PD.

    Also known as: Extraneal

  • DrugGlucose Peritoneal Dialysis Solution

    The treatment modality, number of daily dialysate exchanges, dialysate concentration, exchange dosage of dialysate, duration of dwell, and length of treatment for PD patients as determined by the clinician.

06

What researchers measure

Primary outcomes

  1. Comparison of the incidence of a composite endpoint for technique failure and death

    Technique failure is defined as: * Treatment transferred from PD to HD/PHD \> 30 days; or * PHD, defined as adding HD treatment at least once every 2 weeks in 30 days during PD and requiring long-term combined HD as determined by the investigator. Death is specified as deaths during PD or deaths within 30 days with treatment from PD to HD/PHD

    Time frame: 12 months

Secondary outcomes

  1. Comparison of the proportion of patients with technique failure

    Number and proportion of patients with technique failure

    Time frame: 12 months

  2. Comparison of the incidence of cardiovascular events

    Cardiovascular events include acute myocardial infarction, sudden severe arrhythmia ( a trial fibrillation and arrhythmia requiring hospitalization or medication), hospitalization for heart failure, stroke, and cardiovascular death.

    Time frame: 12 months

  3. Comparison of the incidence of the changes in ejection fraction

    Change of the echocardiographic values from baseline: left ventricular ejection fraction fraction (LVEF)

    Time frame: 12 months

  4. Comparison of all-cause deaths

    All-cause deaths refer to the total number of deaths from any cause within the study timeframe

    Time frame: 12 months

  5. Comparison of medical resource utilization in terms of hospitalizations

    Excluding hospitalizations due to medicare payments or other non-medical issues. For ICO group only

    Time frame: 12 months

  6. Comparison of annual exchange dosage of ICO

    For ICO group only

    Time frame: 12 months

07

Study locations

10 sites
  • Beijing Haidian Hospital
    Beijing, 100000, China
  • Hangzhou Hospital Of Traditional Chinese Medicine
    Hangzhou, 310007, China
  • The Affiliated Hospital of Inner Mongolia Medical University
    Hohhot, 010000, China
  • Nanjing Drum Tower Hospital
    Jiangse, 210008, China
  • Wuxi People's Hospital
    Jiangse, 214023, China
  • The First People's Hospital of Kunshan
    Jiangse, 215300, China
  • Ningbo First Hospital
    Ningbo, 315000, China
  • Shanghai General Hospital
    Shanghai, 200080, China
  • Renji Hospital Shanghai Jaotong University School of Medicine
    Shanghai, 200120, China
  • The Second Affiliated Hospital of Soochow University
    Suzhou, 215004, China
08

References and documents

Individual participant data

Plan to share: Yes — The Sponsor is committed to sharing clinical trial data with external medical experts and scientific researchers in the interest of advancing public health. As such, the Sponsor will supply anonymized Individual Patient Datasets (IPD) and supporting documents (synopsis of clinical study reports, protocol and SAP).

Supporting information: Study protocol, Statistical analysis plan

Time frame: Upon approval of a legitimate research request.

Access criteria: Research requests will be reviewed by qualified medical and scientific experts within the company. If the Sponsor agrees to the release of clinical data for research purposes, the requestor will be required to sign a data sharing agreement (DSA) in order to ensure protection of patient confidentiality and any intellectual property rights of the Sponsor prior to the release of any data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Jan 2026, 18 months.

Of 151 observational studies under Kidney Failure, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 62. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2024
First posted
Jul 9, 2024
StartActual
Jun 28, 2024
Primary completionActual
Jan 27, 2026
CompletionActual
Jan 27, 2026
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06492031
Lead sponsor
Vantive Health LLC
Responsible party
Sponsor
First posted
Jul 9, 2024
Start date
Jun 28, 2024
Primary completion
Jan 27, 2026
Completion
Jan 27, 2026
Last update
Apr 15, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion